investorscraft@gmail.com

Catalyst Pharmaceuticals, Inc. (CPRX)

Previous Close
$21.46
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)90.71323
Intrinsic value (DCF)453.432013
Graham-Dodd Method13.06-39
Graham Formula42.2297

Company Information

355 Alhambra Circle
Coral Gables, FL 33134
United States
Phone: 305 420 3200
Industry: Biotechnology
Sector: Healthcare
CEO: Mr. Richard John Daly M.B.A.
Full Time Employees: 181

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

HomeMenuAccount